RougeTx is developing first-in-class small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction.
Our approach
We are pioneering a new therapeutic approach to vascular disease by targeting the biology of pericytes that regulate angiogenesis and support blood vessel integrity and function. Our aim is to move beyond current symptom management toward urgently needed disease-modifying treatments for vascular diseases.
Lead programme
Our lead RTX-001 programme targets Hereditary Haemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder worldwide.
HHT is characterised by fragile dilated, thin-walled blood vessels that are prone to rupture resulting in recurrent nose and gastro-intestinal bleeding and severe anaemia. Large life-threatening arteriovenous malformations may also occur in the brain, lungs and liver.
Our science
We have identified mechanisms underlying HHT pathology and we are targeting these to develop novel small-molecule drugs and provide effective treatments.
HHT is the second most common inherited bleeding disorder worldwide, affecting 1.4 million people.
© RougeTx
